HALBERD CORP - HALB STOCK NEWS

Halberd Corporation's research at Mississippi State University shows significant reduction in traumatic brain injury markers in early testing of their nasal spray

Halberd Corporation announces progress in the development of a patent-pending nasal spray for traumatic brain injury (TBI). Mississippi State University has collected tissue samples for pre-clinical testing, which will evaluate the effectiveness of the nasal spray in mitigating the negative effects of TBI. The nasal spray targets antigens in cerebrospinal fluid and aims to block the production of inflammatory cytokines and neurotransmitters associated with brain injury. If successful, the nasal spray has potential for wide acceptance in various industries. Halberd plans to seek approval from regulatory bodies for sale and distribution.

Halberd Corporation provides a mid-quarter update on its ongoing projects, including progress on preclinical model testing for its nasal spray for Traumatic Brain Injury (TBI) and eradication of antibiotic-resistant strains of Candida auris and E. coli using laser technology. The company has also submitted multiple funding proposals and applications for support.

Halberd Corporation is set to begin testing a nasal spray designed to counteract the effects of head trauma. The study aims to limit the presence of excess neurotransmitters and decrease hypermetabolism. The goal is to conclude the study within six months.

Halberd Corporation advances its pursuit toward pre-clinical testing of its patent-pending nasal spray designed to counteract excess inflammatory cytokines resulting from head trauma. The study aims to discover the effectiveness of the nasal spray against multiple antigens linked to neurodegenerative conditions like PTSD, Alzheimer's Disease, early onset Alzheimer's Disease, and Epilepsy.

Halberd Corporation (OTC PINK: HALB) reported a productive first quarter of 2023, achieving significant milestones in its research and development efforts. Notably, Halberd successfully eradicated antibiotic-resistant bacteria and fungi using its patented laser technology, as confirmed by the CDC. The company has received additional samples from the CDC for further testing. Additionally, Halberd filed Form 15 with the SEC, removing the YIELD designation from its stock symbol. The company secured a contract with Mississippi State University for preclinical testing of a nasal spray to treat Traumatic Brain Injury (TBI), with 75% of the costs prepaid. Halberd continues to pursue government contracts and partnerships with pharmaceutical companies for FDA approval funding, while maintaining a strategic focus on non-dilutive funding opportunities.